People with mild cognitive impairment due to Alzheimer's can now start Leqembi at home with weekly autoinjector shots after supervised training. The 2026 initiation regimen allows treatment to begin without prior IV infusions for eligible patients. Leqembi Iqlik is subcutaneous lecanemab-irmb, an antibody drug that targets amyloid in early Alzheimer's disease. According to the FDA approval notice shared by Eisai and Biogen, FDA approved it as a starting dose on July 13, 2026.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is eligible?
- What does the weekly dose involve?
- How does injection training work?
- What still needs clinic monitoring?
Who is eligible?
Leqembi and Leqembi Iqlik are only for adults with mild cognitive impairment or mild dementia due to Alzheimer's. Those two stages are together called early Alzheimer's disease.
Patients must also have confirmed amyloid pathology. A clinician confirms it before prescribing and manages follow-up care.
What does the weekly dose involve?
Initiation is 500 mg once weekly, given as two consecutive 250-mg autoinjector injections. According to the U.S.
availability announcement from Eisai and Biogen, each injection takes about 15 seconds. Maintenance is 360 mg once weekly. That lower weekly dose follows the initiation phase and uses the same autoinjector format.
How does injection training work?
Patients or caregivers may give Leqembi Iqlik at home only after at least two consecutive subcutaneous doses under direct guidance. The provider first demonstrates proper use, as described in the Leqembi Iqlik Instructions for Use and Medication Guide. Training covers practical steps patients will repeat each week:.
- Remove the autoinjector 20 minutes before use
- Inject into the abdomen or front of the thigh
- Allow injection into the back of the upper arm only by another person
- Use the video, Welcome Kit tracker, reminder magnet and Demo Kit for practice
What still needs clinic monitoring?
Leqembi retains FDA's boxed warning for amyloid-related imaging abnormalities. These include swelling, called ARIA-E, and bleeding, called ARIA-H. Risk is highest in people with two copies of the ApoE ε4 gene, called homozygotes.
According to the FDA approval announcement, treatment requires baseline and periodic brain MRI monitoring. At-home dosing can eliminate dozens of infusion-center visits and permits switching between IV and subcutaneous routes. MRI surveillance, rapid response to ARIA symptoms and clinician oversight remain mandatory.
You Might Also Like
- MRI and ARIA Monitoring With At-Home Leqembi in 2026: What the News Means for People With Mild Cognitive Impairment
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: What People With Mild Cognitive Impairment Should Know About the News
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
